TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Recursion Pharmaceuticals ( (RXRX) ).
On November 26, 2025, Recursion Pharmaceuticals filed a prospectus supplement to register for resale over 7 million shares of its Class A common stock issued to Tempus AI, Inc. as payment for annual license fees. This move, made under an exemption from registration, highlights Recursion’s strategic financial maneuvers to manage its equity and partnerships, potentially impacting its market positioning and stakeholder interests.
The most recent analyst rating on (RXRX) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Recursion Pharmaceuticals stock, see the RXRX Stock Forecast page.
Spark’s Take on RXRX Stock
According to Spark, TipRanks’ AI Analyst, RXRX is a Neutral.
Recursion Pharmaceuticals faces significant financial challenges, with declining revenues and persistent losses impacting profitability and cash flow. Technical indicators suggest bearish momentum, with the stock trading below key moving averages and approaching oversold territory. The negative P/E ratio and lack of dividend yield further limit the stock’s attractiveness. Despite a positive outlook from the earnings call, the company’s financial performance and technical indicators weigh heavily on the overall score.
To see Spark’s full report on RXRX stock, click here.
More about Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. operates in the biotechnology industry, focusing on the development of drugs through the use of advanced technology and data-driven approaches. The company is known for leveraging machine learning and artificial intelligence to accelerate drug discovery and development processes.
Average Trading Volume: 42,426,469
Technical Sentiment Signal: Sell
Current Market Cap: $2.28B
Find detailed analytics on RXRX stock on TipRanks’ Stock Analysis page.